1887

Abstract

Summary

Infection with human cytomegalovirus (CMV) is characterized by cytological changes which are readily visualized by electron microscopy using ultrathin sections of infected cells. Treatment of such cells with 9-(l ,3-dihydroxy-2-propoxymethyl)guanine (DHPG), a potent inhibitor of CMV, is effective when initiated at early or late times after infection and the response to such treatment has been studied by fine structural analysis. Inhibition of viral DNA synthesis by DHPG treatment (50 μ) late in virus infection resulted in a cessation of virus growth accompanied by a lack of development and possible regression in skein-like intranuclear inclusions together with a depletion in cytoplasmic dense bodies. Such changes were accompanied by the appearance of nuclear dense bodies. These were also present when virus growth was reduced (5 μ-DHPG) rather than completely inhibited (50 μ-DHPG) by treatment initiated from the time of infection. The nuclear bodies were predominantly of a reticular type structure after the early treatment but mainly of a homogeneous form when virus growth was interrupted at late times. Their presence appeared to be connected with the ability of infected cells to initiate the synthesis of late proteins and their morphology may relate to the extent of such protein synthesis. Unlike cytoplasmic dense bodies, provisional findings on the characterization of the nuclear bodies suggested that the 69K matrix protein was not present in abundance.

Keyword(s): CMV , electron microscopy and human/DHPG
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-68-6-1553
1987-06-01
2022-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/68/6/JV0680061553.html?itemId=/content/journal/jgv/10.1099/0022-1317-68-6-1553&mimeType=html&fmt=ahah

References

  1. Bach M. C., Bagwell S. P., Knapp N. P., Davis K. M., Hedstrom P. S. 1985; 9-(l,3-dihydroxy-2- propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 103:381–382
    [Google Scholar]
  2. Betts R. F. 1982; Cytomegalovirus infection in transplant patients. Progress in Medical Virology 28:44–64
    [Google Scholar]
  3. Biron K. K., Stanat S. C., Surrell J. B., Fyfe J. A., Keller P. M., Lambe C. U., Nelson D. J. 1985; Metabolic activation of the nucleoside analog 9-([2-hydroxy-l-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proceedings of the National Academy of Sciences U.S.A.: 822473–2477
    [Google Scholar]
  4. Cavallo T., Graves K., Cole N. L., Albrecht T. 1981; Cytomegalovirus: an ultrastructural study of the morphogenesis of nuclear inclusions in human cell culture. Journal of General Virology 56:97–104
    [Google Scholar]
  5. Cheng Y. C., Huang E. S., Lin J. C., Mar E.-C., Pagano J. S., Dutschman G. E., Grill S. P. 1983; Unique spectrum of activity of 9-[(l,3-dihydroxy-2-propoxy)methyl]guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proceedings of the National Academy of Sciences U.S.A.: 802767–2770
    [Google Scholar]
  6. COLLABORATIVE DHPG TREATMENT STUDY GROUP 1986; Treatment of serious cytomegalovirus infections with 9-(l,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. New England Journal of Medicine 314801–805
    [Google Scholar]
  7. Felsenstein D., D’Amico D. J., Hirsch M. S., Neumeyer D. A., Cederberg D. M., De Miranda P., Schooley R. T. 1985; Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine. Annals of Internal Medicine 103:377–380
    [Google Scholar]
  8. Geballe A. P., Leach F. S., Mocarski E. S. 1986; Regulation of cytomegalovirus late gene expression: genes are controlled by post-transcriptional events. Journal of Virology 57:864–874
    [Google Scholar]
  9. Gehrz R .C., Knorr S. O., Marker S. C., Kalis J. M., Balfour H. H.Jr 1977; Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet ii:844–847
    [Google Scholar]
  10. Gibson W. 1983; Protein counterparts of human and simian cytomegaloviruses. Virology 128:391–406
    [Google Scholar]
  11. Gibson W., Irmiere A. 1984; Selection of particles and proteins for use as human cytomegalovirus vaccines. In CMV: Pathogenesis and Prevention of Human Infection. Birth Defects.Original Article Series 20 pp Plotkin S. A., Michelson S., Pagano J., Rapp F. Edited by March of Dimes Birth Defects Foundation;
    [Google Scholar]
  12. Goodheart c. R., Mcallister R. M., Filbert J. E. 1964; Human cytomegalovirus DNA synthesis and migration in infected cells studied autoradiographically. Virology 23:603–608
    [Google Scholar]
  13. Hanshaw J. B. 1966; Congenital and acquired cytomegalovirus infection. Pediatric Clinics of North America 13:279–293
    [Google Scholar]
  14. Isom H. C. 1979; Stimulation of ornithine decarboxylase by human cytomegalovirus. Journal of General Virology 42:265–278
    [Google Scholar]
  15. Iwasaki Y., Furukawa T., Plotkin S. A., Koprowski H. 1973; Ultrastructural study on the sequence of human cytomegalovirus infection in human diploid cells. Archiv für die gesamte Virusforschung 40:311–324
    [Google Scholar]
  16. Mcallister R. M., Straw R. M., Filbert J. E., Goodheart C. R. 1963; Human cytomegalovirus. Cytochemical observations of intracellular lesion development correlated with viral synthesis and release. Virology 19:521–531
    [Google Scholar]
  17. McCracken G. H., Shinefield H. R., Cobb K., Rausen A. R. 1969; Congenital cytomegalic inclusion disease: a longitudinal study of 20 patients. American Journal of Diseases of Children 117:522–539
    [Google Scholar]
  18. Mar E.-C., Cheng Y.-C., Huang E.-S. 1983; Effect of 9-(l,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 24:518–521
    [Google Scholar]
  19. Mar E.-C., Chiou J.-F., Cheng Y.-C., Huang E.-S. 1985; Inhibition of cellular DNA polymerase and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(l,3-dihydroxy-2-propoxymethyl)guanine. Journal of Virology 53:776–780
    [Google Scholar]
  20. Martin A. M., Kurtz S. M. 1966; Cytomegalic inclusion disease. Archives of Pathology 82:27–34
    [Google Scholar]
  21. Post J. D., Hensley G. T., Moskowitz L. B., Fischel M. 1986; Cytomegalic inclusion virus encephalitis in patients with AIDS: clinical and pathologic correlation. American Journal of Roentgenology 146:1229–1233
    [Google Scholar]
  22. Ryder T. A., Mackenzie M. L. 1981; The routine preparation of seminal fluid specimens for transmission electron microscopy. Journal of Clinical Pathology 34:1006–1009
    [Google Scholar]
  23. Sarov I., Abady i. 1975; The morphogenesis of human cytomegalovirus: isolation and polypeptide characterization of cytomegalovirus and dense bodies. Virology 66:464–473
    [Google Scholar]
  24. Shepp D. H., Dandliker P. S., De Miranda P., Burnette T.C, Kirk L. E., Meyers J. D. 1985; Activity of 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Annals of Internal Medicine 103:368–373
    [Google Scholar]
  25. Stagno S., Reynolds D. w., Tsiantos A., Fuccillo D. A., Long w., Alford C. A. 1975; Comparative serial virologic and serologic studies of symptomatic and sub-clinical congenitally and natally acquired cytomegalovirus infections. Journal of Infectious Diseases 132:568–577
    [Google Scholar]
  26. Starr S. E., Tolpin M. D., Friedman H. M., Paucker K., Plotkin s. A. 1979; Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers. Journal of Infectious Diseases 140:500–505
    [Google Scholar]
  27. Stinski M. F. 1978; Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. Journal of Virology 26:686–701
    [Google Scholar]
  28. Tyms A. S., Williamson j. D. 1982; Inhibitors of polyamine biosynthesis block human cytomegalovirus replication. Nature; London: 297690–691
    [Google Scholar]
  29. Tyms A. S., Stevens R. J., Mobberley M. A., Ryder T. A., Jeffries D. J. 1984; Human cytomegalovirus infections in vitro after treatment with Arildone. Journal of General Virology 65:2129–2139
    [Google Scholar]
  30. Tyms A. S., Davis J. M., Clarke J. R. 1987; Synthesis of cytomegalovirus DNA is an antiviral target late in virus growth. Journal of General Virology 68:1563–1573
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-68-6-1553
Loading
/content/journal/jgv/10.1099/0022-1317-68-6-1553
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error